Correction: NF2 loss promotes oncogenic RAS-induced thyroid cancers via YAP-dependent transactivation of RAS proteins and sensitizes them to MEK inhibition (Cancer Discov. (2015), 10.1158/2159-8290.CD-15-0330);NF2 loss promotes oncogenic RAS-induced thyroid cancers via YAP-dependent transactivation of RAS proteins and sensitizes them to MEK inhibition

Cancer Discovery

Volumn 5, Issue 11, 2015, Pages 1178-1193

  Garcia Rendueles, Maria E R ^a   Ricarte Filho, Julio C ^a   Untch, Brian R ^a   Landa, Iňigo ^a   Knauf, Jeffrey A ^a   Voza, Francesca ^a   Smith, Vicki E ^a   Ganly, Ian ^a   Taylor, Barry S ^a   Persaud, Yogindra ^a   Oler, Gisele ^a   Fang, Yuqiang ^a   Jhanwar, Suresh C ^a   Viale, Agnes ^a   Heguy, Adriana ^a   Huberman, Kety H ^a   Giancotti, Filippo ^a,b   Ghossein, Ronald ^a   Fagin, James A ^a,b  

^a MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

^b WEILL CORNELL MEDICAL COLLEGE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ACTIN; CHECKPOINT KINASE 2; COMPLEMENTARY DNA; CONNECTIVE TISSUE GROWTH FACTOR; CRK LIKE PROTEIN; CYCLIN D1; DOXYCYCLINE; E1A ASSOCIATED P300 PROTEIN; K RAS PROTEIN; MERLIN; MESSENGER RNA; MITOGEN ACTIVATED PROTEIN KINASE 1; MITOGEN ACTIVATED PROTEIN KINASE KINASE; P21 ACTIVATED KINASE; RAC1 PROTEIN; RAF PROTEIN; RAS PROTEIN; TRANSCRIPTION FACTOR; TRANSCRIPTION FACTOR YAP; UNCLASSIFIED DRUG; VERTEPORFIN; MITOGEN ACTIVATED PROTEIN KINASE; NUCLEAR PROTEIN; PROTEIN BINDING; PROTEIN KINASE INHIBITOR; YY1AP1 PROTEIN, HUMAN;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CHROMATIN IMMUNOPRECIPITATION; CHROMOSOME 22Q; CHROMOSOME LOSS; COLONY FORMATION; CONTROLLED STUDY; DNA ISOLATION; ECHOGRAPHY; FEMALE; FLUORESCENCE IN SITU HYBRIDIZATION; GENE DOSAGE; GENE EXPRESSION; GENE FREQUENCY; GENE MUTATION; GENE SEQUENCE; GENE SILENCING; HUMAN; HUMAN CELL; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; MALE; MOUSE; NONHUMAN; ONCOGENE H RAS; ONCOGENE N RAS; POORLY DIFFERENTIATED THYROID CANCER; PROTEIN DEPLETION; PROTEIN EXPRESSION; REAL TIME POLYMERASE CHAIN REACTION; RNA ISOLATION; SINGLE NUCLEOTIDE POLYMORPHISM; THYROID CANCER CELL LINE; TRANSACTIVATION; WESTERN BLOTTING; ANIMAL; ANTAGONISTS AND INHIBITORS; BINDING SITE; BIOLOGICAL MODEL; CANCER STAGING; CELL TRANSFORMATION; CHROMOSOME 22; CHROMOSOME DELETION; COPY NUMBER VARIATION; DISEASE MODEL; DRUG EFFECTS; DRUG RESISTANCE; GENE DELETION; GENE EXPRESSION REGULATION; GENE ORDER; GENE TARGETING; GENETICS; METABOLISM; NUCLEOTIDE MOTIF; ONCOGENE RAS; PATHOLOGY; POSITION WEIGHT MATRIX; PROMOTER REGION; SIGNAL TRANSDUCTION; THYROID NEOPLASMS; TRANSCRIPTION INITIATION; TRANSGENIC MOUSE; TUMOR CELL LINE;

ANIMALS; BINDING SITES; CELL LINE, TUMOR; CELL TRANSFORMATION, NEOPLASTIC; CHROMOSOME DELETION; CHROMOSOMES, HUMAN, PAIR 22; DISEASE MODELS, ANIMAL; DNA COPY NUMBER VARIATIONS; DRUG RESISTANCE, NEOPLASM; GENE DELETION; GENE EXPRESSION REGULATION, NEOPLASTIC; GENE ORDER; GENE TARGETING; GENES, RAS; HUMANS; MICE; MICE, TRANSGENIC; MITOGEN-ACTIVATED PROTEIN KINASES; MODELS, BIOLOGICAL; NEOPLASM STAGING; NEUROFIBROMIN 2; NUCLEAR PROTEINS; NUCLEOTIDE MOTIFS; POSITION-SPECIFIC SCORING MATRICES; PROMOTER REGIONS, GENETIC; PROTEIN BINDING; PROTEIN KINASE INHIBITORS; SIGNAL TRANSDUCTION; THYROID NEOPLASMS; TRANSCRIPTION FACTORS; TRANSCRIPTIONAL ACTIVATION;

EID: 84946232572     PISSN: 21598274     EISSN: 21598290     Source Type: Journal    
DOI: 10.1158/2159-8290.CD-19-1108     Document Type: Erratum

References (64)

1. Rouleau GA, Merel P, Lutchman M, Sanson M, Zucman J, Marineau C, et al. Alteration in a new gene encoding a putative membrane- organizing protein causes neuro-fibromatosis type 2. Nature 1993; 363: 515-21.
2. Hamaratoglu F, Willecke M, Kango-Singh M, Nolo R, Hyun E, Tao C, et al. The tumour-suppressor genes NF2/Merlin and Expanded act through Hippo signalling to regulate cell proliferation and apoptosis. Nat Cell Biol 2006; 8: 27-36.
3. Curto M, McClatchey AI. Nf2/Merlin: a coordinator of receptor signalling and intercellular contact. Br J Cancer 2008; 98: 256-62.
4. Curto M, Cole BK, Lallemand D, Liu CH, McClatchey AI. Contactdependent inhibition of EGFR signaling by Nf2/Merlin. J Cell Biol 2007; 177: 893-903.
5. Shaw RJ, Paez JG, Curto M, Yaktine A, Pruitt WM, Saotome I, et al. The Nf2 tumor suppressor, merlin, functions in Rac-dependent signaling. Dev Cell 2001; 1: 63-72.
6. Sherman LS, Gutmann DH. Merlin: hanging tumor suppression on the Rac. Trends Cell Biol 2001; 11: 442-4.
7. Yi C, Wilker EW, Yaffe MB, Stemmer-Rachamimov A, Kissil JL. Validation of the p21-activated kinases as targets for inhibition in neurofi- bromatosis type 2. Cancer Res 2008; 68: 7932-7.
8. James MF, Han S, Polizzano C, Plotkin SR, Manning BD, Stemmer- Rachamimov AO, et al. NF2/merlin is a novel negative regulator of mTOR complex 1, and activation of mTORC1 is associated with meningioma and schwannoma growth. Mol Cell Biol 2009; 29: 4250-61.
9. Lopez-Lago MA, Okada T, Murillo MM, Socci N, Giancotti FG. Loss of the tumor suppressor gene NF2, encoding merlin, constitutively activates integrin-dependent mTORC1 signaling. Mol Cell Biol 2009; 29: 4235-49.
10. Li W, You L, Cooper J, Schiavon G, Pepe-Caprio A, Zhou L, et al. Merlin/NF2 suppresses tumorigenesis by inhibiting the E3 ubiquitin ligase CRL4(DCAF1) in the nucleus. Cell 2010; 140: 477-90.
11. Zhang H, Liu CY, Zha ZY, Zhao B, Yao J, Zhao S, et al. TEAD transcription factors mediate the function of TAZ in cell growth and epithelial-mesenchymal transition. J Biol Chem 2009; 284: 13355-62.
12. Zhao B, Ye X, Yu J, Li L, Li W, Li S, et al. TEAD mediates YAPdependent gene induction and growth control. Genes Dev 2008; 22: 1962-71.
13. Dong J, Feldmann G, Huang J, Wu S, Zhang N, Comerford SA, et al. Elucidation of a universal size-control mechanism in Drosophila and mammals. Cell 2007; 130: 1120-33.
14. Liu-Chittenden Y, Huang B, Shim JS, Chen Q, Lee SJ, Anders RA, et al. Genetic and pharmacological disruption of the TEAD-YAP complex suppresses the oncogenic activity of YAP. Genes Dev 2012; 26: 1300-5.
15. Harvey KF, Zhang X, Thomas DM. The Hippo pathway and human cancer. Nat Rev Cancer 2013; 13: 246-57
16. Iyer G, Hanrahan AJ, Milowsky MI, Al-Ahmadie H, Scott SN, Janakiraman M, et al. Genome sequencing identifies a basis for everolimus sensitivity. Science 2012; 338: 221.
17. Houshmandi SS, Emnett RJ, Giovannini M, Gutmann DH. The neurofibromatosis 2 protein, merlin, regulates glial cell growth in an ErbB2- and Src-dependent manner. Mol Cell Biol 2009; 29: 1472-86.
18. Zhang N, Bai H, David KK, Dong J, Zheng Y, Cai J, et al. The Merlin/ NF2 tumor suppressor functions through the YAP oncoprotein to regulate tissue homeostasis in mammals. Dev Cell 2010; 19: 27-38.
19. Benhamouche S, Curto M, Saotome I, Gladden AB, Liu CH, Giovannini M, et al. Nf2/Merlin controls progenitor homeostasis and tumorigenesis in the liver. Genes Dev 2010; 24: 1718-30.
20. Kimura ET, Nikiforova MN, Zhu Z, Knauf JA, Nikiforov YE, Fagin JA. High prevalence of BRAF mutations in thyroid cancer: genetic evidence for constitutive activation of the RET/PTC-RAS-BRAF signaling pathway in papillary thyroid carcinoma. Cancer Res 2003; 63: 1454-7.
21. Volante M, Rapa I, Gandhi M, Bussolati G, Giachino D, Papotti M, et al. RAS mutations are the predominant molecular alteration in poorly differentiated thyroid carcinomas and bear prognostic impact. J Clin Endocrinol Metab 2009; 94: 4735-41.
22. Ricarte-Filho JC, Ryder M, Chitale DA, Rivera M, Heguy A, Ladanyi M, et al. Mutational profile of advanced primary and metastatic radioactive iodine-refractory thyroid cancers reveals distinct pathogenetic roles for BRAF, PIK3CA, and AKT1. Cancer Res 2009; 69: 4885-93.
23. Smallridge RC, Marlow LA, Copland JA. Anaplastic thyroid cancer: molecular pathogenesis and emerging therapies. Endocr Relat Cancer 2009; 16: 17-44.
24. Cancer Genome Research Atlas Network. Integrated genomic characterization of papillary thyroid cancer. Cell 2014; 159: 676-80.
25. Zucman-Rossi J, Legoix P, Der SH, Cheret G, Sor F, Bernardi A, et al. NF2 gene in neurofibromatosis type 2 patients. Hum Mol Genet 1998; 7: 2095-101.
26. Lepont P, Stickney JT, Foster LA, Meng JJ, Hennigan RF, Ip W. Point mutation in the NF2 gene of HEI-193 human schwannoma cells results in the expression of a merlin isoform with attenuated growth suppressive activity. Mutat Res 2008; 637: 142-51.
27. Serrano I, McDonald PC, Lock F, Muller WJ, Dedhar S. Inactivation of the Hippo tumour suppressor pathway by integrin-linked kinase. Nat Commun 2013; 4: 2976.
28. Bianchi AB, Hara T, Ramesh V, Gao J, Klein-Szanto AJ, Morin F, et al. Mutations in transcript isoforms of the neurofibromatosis 2 gene in multiple human tumour types. Nat Genet 1994; 6: 185-92.
29. Yang C, Asthagiri AR, Iyer RR, Lu J, Xu DS, Ksendzovsky A, et al. Missense mutations in the NF2 gene result in the quantitative loss of merlin protein and minimally affect protein intrinsic function. Proc Natl Acad Sci U S A 2011; 108: 4980-5.
30. Kimura Y, Koga H, Araki N, Mugita N, Fujita N, Takeshima H, et al. The involvement of calpain-dependent proteolysis of the tumor suppressor NF2 (merlin) in schwannomas and meningiomas. Nat Med 1998; 4: 915-22.
31. Chen X, Mitsutake N, LaPerle K, Akeno N, Zanzonico P, Longo VA, et al. Endogenous expression of Hras(G12V) induces developmental defects and neoplasms with copy number imbalances of the oncogene. Proc Natl Acad Sci U S A 2009; 106: 7979-84.
32. Bashour AM, Meng JJ, Ip W, MacCollin M, Ratner N. The neurofi- bromatosis type 2 gene product, merlin, reverses the F-actin cytoskeletal defects in primary human schwannoma cells. Mol Cell Biol 2002; 22: 1150-7.
33. Yi C, Troutman S, Fera D, Stemmer-Rachamimov A, Avila JL, Christian N, et al. A tight junction-associated Merlin-angiomotin complex mediates Merlin’s regulation of mitogenic signaling and tumor suppressive functions. Cancer Cell 2011; 19: 527-40.
34. Michels S, Schmidt-Erfurth U. Photodynamic therapy with verteporfin: a new treatment in ophthalmology. Semin Ophthalmol 2001; 16: 201–6.
35. Finney RE, Bishop JM. Predisposition to neoplastic transformation caused by gene replacement of H-ras1. Science 1993; 260: 1524–7.
36. Bremner R, Balmain A. Genetic changes in skin tumor progression: correlation between presence of a mutant ras gene and loss of heterozygosity on mouse chromosome 7. Cell 1990; 61: 407-17.
37. Chen X, Makarewicz JM, Knauf JA, Johnson LK, Fagin JA. Transformation by Hras is consistently associated with mutant allele copy gains and is reversed by farnesyl transferase inhibition. Oncogene 2013; 10.
38. Xu J, Haigis KM, Firestone AJ, McNerney ME, Li Q, Davis E, et al. Dominant role of oncogene dosage and absence of tumor suppressor activity in Nras-driven hematopoietic transformation. Cancer Discov 2013; 3: 993-1001.
39. Namba H, Gutman RA, Matsuo K, Alvarez A, Fagin JA. H-ras protooncogene mutations in human thyroid neoplasms. J Clin Endocrinol Metab 1990; 71: 223-9.
40. Johnson SM, Grosshans H, Shingara J, Byrom M, Jarvis R, Cheng A, et al. RAS is regulated by the let-7 microRNA family. Cell 2005; 120: 635-47.
41. Johnson CD, Esquela-Kerscher A, Stefani G, Byrom M, Kelnar K, Ovcharenko D, et al. The let-7 microRNA represses cell proliferation pathways in human cells. Cancer Res 2007; 67: 7713-22.
42. Kumar MS, Erkeland SJ, Pester RE, Chen CY, Ebert MS, Sharp PA, et al. Suppression of non-small cell lung tumor development by the let-7 microRNA family. Proc Natl Acad Sci U S A 2008; 105: 3903-8.
43. Lamar JM, Stern P, Liu H, Schindler JW, Jiang ZG, Hynes RO. The Hippo pathway target, YAP, promotes metastasis through its TEAD-interaction domain. Proc Natl Acad Sci U S A 2012; 109: E2441-E2450.
44. Xie Q, Chen J, Feng H, Peng S, Adams U, Bai Y, et al. YAP/TEADmediated transcription controls cellular senescence. Cancer Res 2013; 73: 3615-24.
45. Lee KP, Lee JH, Kim TS, Kim TH, Park HD, Byun JS, et al. The Hippo- Salvador pathway restrains hepatic oval cell proliferation, liver size, and liver tumorigenesis. Proc Natl Acad Sci U S A 2010; 107: 8248-53.
46. Lu L, Li Y, Kim SM, Bossuyt W, Liu P, Qiu Q, et al. Hippo signaling is a potent in vivo growth and tumor suppressor pathway in the mammalian liver. Proc Natl Acad Sci U S A 2010; 107: 1437-42.
47. Urtasun R, Latasa MU, Demartis MI, Balzani S, Goni S, Garcia- Irigoyen O, et al. Connective tissue growth factor autocriny in human hepatocellular carcinoma: oncogenic role and regulation by epidermal growth factor receptor/yes-associated protein-mediated activation. Hepatology 2011; 54: 2149-58.
48. Kapoor A, Yao W, Ying H, Hua S, Liewen A, Wang Q, et al. Yap1 activation enables bypass of oncogenic Kras addiction in pancreatic cancer. Cell 2014; 158: 185-97.
49. Shao DD, Xue W, Krall EB, Bhutkar A, Piccioni F, Wang X, et al. KRAS and YAP1 converge to regulate EMT and tumor survival. Cell 2014; 158: 171-84.
50. Zhang W, Nandakumar N, Shi Y, Manzano M, Smith A, Graham G, et al. Downstream of mutant KRAS, the transcription regulator YAP is essential for neoplastic progression to pancreatic ductal adenocarcinoma. Sci Signal 2014; 7: ra42.
51. Lian I, Kim J, Okazawa H, Zhao J, Zhao B, Yu J, et al. The role of YAP transcription coactivator in regulating stem cell self-renewal and differentiation. Genes Dev 2010; 24: 1106-18.
52. McClatchey AI, Saotome I, Mercer K, Crowley D, Gusella JF, Bronson RT, et al. Mice heterozygous for a mutation at the Nf2 tumor suppressor locus develop a range of highly metastatic tumors. Genes Dev 1998; 12: 1121-33.
53. Manchanda PK, Jones GN, Lee AA, Pringle DR, Zhang M, Yu L, et al. Rac1 is required for Prkar1a-mediated Nf2 suppression in Schwann cell tumors. Oncogene 2013; 32: 3491-9.
54. Schweppe RE, Klopper JP, Korch C, Pugazhenthi U, Benezra M, Knauf JA, et al. Deoxyribonucleic acid profiling analysis of 40 human thyroid cancer cell lines reveals cross-contamination resulting in cell line redundancy and misidentification. J Clin Endocrinol Metab 2008; 93: 4331-41.
55. Won HH, Scott SN, Brannon AR, Shah RH, Berger MF. Detecting somatic genetic alterations in tumor specimens by exon capture and massively parallel sequencing. J Vis Exp 2013; e50710.
56. Venkatraman ES, Olshen AB. A faster circular binary segmentation algorithm for the analysis of array CGH data. Bioinformatics 2007; 23: 657-63.
57. Taylor BS, Barretina J, Socci ND, Decarolis P, Ladanyi M, Meyerson M, et al. Functional copy-number alterations in cancer. PLoS One 2008; 3: e3179.
58. Robinson JT, Thorvaldsdottir H, Winckler W, Guttman M, Lander ES, Getz G, et al. Integrative genomics viewer. Nat Biotechnol 2011; 29: 24-6.
59. Kusakabe T, Kawaguchi A, Kawaguchi R, Feigenbaum L, Kimura S. Thyrocyte-specific expression of Cre recombinase in transgenic mice. Genesis 2004; 39: 212-6.
60. Giovannini M, Robanus-Maandag E, van der Valk M, Niwa-Kawakita M, Abramowski V, Goutebroze L, et al. Conditional biallelic Nf2 mutation in the mouse promotes manifestations of human neurofi- bromatosis type 2. Genes Dev 2000; 14: 1617-30.
61. Jonkers J, Meuwissen R, van der Gulden H, Peterse H, van der Valk M, Berns A. Synergistic tumor suppressor activity of BRCA2 and p53 in a conditional mouse model for breast cancer. Nat Genet 2001; 29: 418-25.
62. Trotman LC, Niki M, Dotan ZA, Koutcher JA, Di CA, Xiao A, et al. Pten dose dictates cancer progression in the prostate. PLoS Biol 2003; 1: E59.
63. Xiao GH, Beeser A, Chernoff J, Testa JR. p21-activated kinase links Rac/Cdc42 signaling to merlin. J Biol Chem 2002; 277: 883-6.
64. Overholtzer M, Zhang J, Smolen GA, Muir B, Li W, Sgroi DC, et al. Transforming properties of YAP, a candidate oncogene on the chromosome 11q22 amplicon. Proc Natl Acad Sci U S A 2006; 103: 12405-10.